RET and non-small cell lung carcinoma: The stage at which a patient is provided genomic biomarker testing for RET alterations (if available) can also depend on factors such as family history of multiple endocrine neoplasia (for patients with MTC), or history of smoking (for patients with NSCLC) [10, 11].